Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Adults With Type 1 Diabetes Undergoing Islet Cell Transplant

Next Previous
X
Search
Trial Profile

An Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Adults With Type 1 Diabetes Undergoing Islet Cell Transplant

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tegoprubart (Primary) ; Etanercept; Mycophenolate mofetil
  • Indications Islet cell transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Anelixis Therapeutics

    • Most Recent Events

    • 08 Aug 2022 Status changed from recruiting to withdrawn prior to enrolment.
    • 02 Sep 2021 Planned number of patients changed from 12 to 6.
    • 30 Mar 2021 According to an Eledon Pharmaceuticals media release, the company has received clearance from Health Canada to proceed with the initiation of this study. The company expects to enroll first patient in 2Q 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top